StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
9220.T$1236.00-1.12%
Fair $1236.00+0.0%

9220.T

FB Care Service Co.,Ltd.

Healthcare / Medical Care FacilitiesTokyo

$1236.00

-14.00 (-1.12%)

Fairly Valued+0.0%Fair Value $1236.00Fund rank 34/100 · Data gapFallback financials|
SA 56/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $465.8M · quality 64.7/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 71/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

56/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 9220.TLocal privado en este navegador · FB Care Service Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3.0B

P/E

6.9x

↓

EV/EBITDA

4.2x

↓

ROE

11.2%

↑

Gross Margin

15.5%

↓

Debt/Equity

0.80

↑
52-Week Range$1236
$962$1324

TradingView lightweight chart

9220.T price, volumen y niveles de valoración

Último $1,236Periodo -28.7%
Fair value: $1,236

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+6.1%

FCF CAGR

-2.0%

FCF margin

7.4%

FCF / Net income

2.00x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $10.97B · net income $406.4M · FCF $812.9M

2022-FY → 2025-FY

Gross margin

15.5%-1.5% pts

Operating margin

6.0%-1.1% pts

Net margin

3.7%-2.1% pts

FCF margin

7.4%-2.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$10.97B$10.97B$10.36B$9.62B$9.19B
Net Income$406.4M$406.4M$523.4M$444.9M$528.7M
EBITDA$1.02B$1.02B$1.16B$1.05B$1.07B
EPS152.00152.00195.60167.39240.32
Gross Margin15.5%15.5%14.4%16.2%16.9%
Operating Margin6.0%6.0%5.1%5.7%7.1%
Net Margin3.7%3.7%5.1%4.6%5.8%
Balance Sheet
Debt/Equity0.800.801.061.271.89
Current Ratio1.631.63———
Cash Flow
Free Cash Flow$812.9M$812.9M$465.8M$207.5M$864.8M
Returns
ROE11.2%11.2%15.0%14.6%26.3%
Valuation
P/E6.916.915.666.966.79
EV/EBITDA4.174.173.694.365.25
P/B0.910.910.851.021.79
Growth & Yield
Revenue Growth5.9%5.9%7.7%4.7%—
EPS Growth-22.3%-22.3%16.9%-30.3%—
Dividend Yield4.0%4.0%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-10.3%

fácil

EPS terminal req.

$109.67

Spread vs growth

-12.0%

5Y implied EPS CAGR

-2.7%

fácil

EPS terminal req.

$132.71

Spread vs growth

-19.6%

10Y implied EPS CAGR

3.5%

fácil

EPS terminal req.

$213.72

Spread vs growth

-25.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +27.7%

Total return

+27.7%

Start / end P/E

5.1x → 8.1x

EPS bridge

195.60 → 152.00

Residual

-13.2%

EPS growth-22.3%
Multiple rerating+59.2%
Dividend+4.0%
Residual / FX / buybacks / cross-term-13.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.